---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-050307"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-04-23T23:59:59+00:00"
generated_at: "2026-06-03T13:14:57.729340+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics reports positive Phase 1 data for VCN-01 in pediatric retinoblastoma and exclusive license from SJD

## Summary
- Phase 1 trial of intravitreal VCN-01 in 9 evaluable patients with refractory retinoblastoma determined positive by Monitoring Committee.
- Safety: no dose-limiting toxicities; most adverse events Grade 1 or 2; no Grade 3+ ocular or systemic toxicities.
- Antitumor activity: 4 patients had unequivocal improvement in vitreous seed density; eye enucleation avoided in 3 patients (1 retained eye after 4 years).
- Theriva will receive exclusive worldwide license and related patents from Sant Joan de Déu-Barcelona Children's Hospital for advanced retinoblastoma treatment.

## SEC filing metadata
- accession: 0001104659-24-050307
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924050307/0001104659-24-050307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924050307/tm2412300d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-050307
- JSON: https://secwatch.observer/filing/0001104659-24-050307.json
- Plain text: https://secwatch.observer/filing/0001104659-24-050307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.